<code id='F82A116B62'></code><style id='F82A116B62'></style>
    • <acronym id='F82A116B62'></acronym>
      <center id='F82A116B62'><center id='F82A116B62'><tfoot id='F82A116B62'></tfoot></center><abbr id='F82A116B62'><dir id='F82A116B62'><tfoot id='F82A116B62'></tfoot><noframes id='F82A116B62'>

    • <optgroup id='F82A116B62'><strike id='F82A116B62'><sup id='F82A116B62'></sup></strike><code id='F82A116B62'></code></optgroup>
        1. <b id='F82A116B62'><label id='F82A116B62'><select id='F82A116B62'><dt id='F82A116B62'><span id='F82A116B62'></span></dt></select></label></b><u id='F82A116B62'></u>
          <i id='F82A116B62'><strike id='F82A116B62'><tt id='F82A116B62'><pre id='F82A116B62'></pre></tt></strike></i>

          knowledge

          knowledge

          author:comprehensive    Page View:41
          Buildings like hospitals and banks on a web with people operating laptops and phones — health tech coverage from STAT
          Adobe

          For years, the playbook for many companies that wanted to market digital therapeutics was stupid simple: Sell it like a prescription drug.

          But just because it was simple didn’t mean it was going to work.

          advertisement

          The bankruptcy of Pear Therapeutics last year proved that selling software-based treatments like drugs is harder than anticipated. Pear received Food and Drug Administration clearance for its app treating substance use disorders and insomnia but insurers mostly refused to cover the novel treatments. Even after hitting roadblock after roadblock, the company stuck to its original plan and ended up vaporizing over $400 million in investment before finally throwing in the towel.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more
          Menendez indictment could see pharma lose a key ally
          Menendez indictment could see pharma lose a key ally

          Sen.BobMenendez(D-N.J.)MichaelM.Santiago/GettyImagesWASHINGTON—WithmountingcallsforembattledSen.BobM

          read more
          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more

          Did you have Obamacare on your GOP debate bingo card?

          AlexHogan/STATYou’rereadingthewebeditionofD.C.Diagnosis. Signuphere toreceivethisnewsletterinyourinb